BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,694 | -22.4% | 68,964 | -6.9% | 0.33% | -20.2% |
| Q2 2023 | $6,046 | +9.0% | 74,064 | -0.9% | 0.41% | +3.8% |
| Q1 2023 | $5,547 | -18.0% | 74,764 | -8.4% | 0.40% | -22.0% |
| Q4 2022 | $6,768 | -99.9% | 81,664 | +296.6% | 0.51% | +9.5% |
| Q3 2022 | $5,848,000 | -18.3% | 20,591 | -0.2% | 0.46% | -15.3% |
| Q2 2022 | $7,155,000 | -19.9% | 20,641 | 0.0% | 0.55% | -10.7% |
| Q1 2022 | $8,938,000 | -16.3% | 20,641 | +0.0% | 0.61% | -13.5% |
| Q4 2021 | $10,673,000 | +5.0% | 20,631 | -1.7% | 0.71% | -6.2% |
| Q3 2021 | $10,167,000 | +30.2% | 20,981 | +2.6% | 0.76% | +19.0% |
| Q2 2021 | $7,811,000 | 0.0% | 20,451 | 0.0% | 0.64% | 0.0% |
| Q1 2021 | $7,811,000 | +21.8% | 20,451 | +1.2% | 0.64% | +14.8% |
| Q4 2020 | $6,415,000 | +28.2% | 20,201 | 0.0% | 0.55% | +27.4% |
| Q3 2020 | $5,004,000 | -4.5% | 20,201 | +1.8% | 0.44% | -14.7% |
| Q2 2020 | $5,242,000 | +58.4% | 19,851 | +13.8% | 0.51% | +33.2% |
| Q1 2020 | $3,309,000 | -16.0% | 17,451 | -2.8% | 0.38% | +3.8% |
| Q4 2019 | $3,940,000 | +12.2% | 17,951 | 0.0% | 0.37% | +2.5% |
| Q3 2019 | $3,512,000 | -6.2% | 17,951 | 0.0% | 0.36% | -8.6% |
| Q2 2019 | $3,743,000 | +5.6% | 17,951 | +0.6% | 0.39% | -0.5% |
| Q1 2019 | $3,544,000 | +37.2% | 17,851 | 0.0% | 0.40% | +22.2% |
| Q4 2018 | $2,583,000 | -29.1% | 17,851 | 0.0% | 0.32% | -17.3% |
| Q3 2018 | $3,644,000 | +37.2% | 17,851 | -0.6% | 0.39% | +29.8% |
| Q2 2018 | $2,656,000 | -2.0% | 17,951 | 0.0% | 0.30% | -4.4% |
| Q1 2018 | $2,711,000 | +16.6% | 17,951 | 0.0% | 0.32% | +15.3% |
| Q4 2017 | $2,326,000 | +7.2% | 17,951 | 0.0% | 0.27% | +2.2% |
| Q3 2017 | $2,170,000 | +5.9% | 17,951 | +2.9% | 0.27% | +3.1% |
| Q2 2017 | $2,050,000 | +15.6% | 17,451 | 0.0% | 0.26% | +14.0% |
| Q1 2017 | $1,774,000 | -50.6% | 17,451 | -50.0% | 0.23% | -7.7% |
| Q4 2016 | $3,588,000 | +87.8% | 34,902 | +100.0% | 0.25% | -12.4% |
| Q3 2016 | $1,911,000 | -2.9% | 17,451 | 0.0% | 0.28% | -2.8% |
| Q2 2016 | $1,968,000 | +4.3% | 17,451 | -12.5% | 0.29% | +2.5% |
| Q1 2016 | $1,886,000 | +2.9% | 19,951 | -2.0% | 0.28% | +5.2% |
| Q4 2015 | $1,832,000 | -2.7% | 20,351 | 0.0% | 0.27% | -9.4% |
| Q3 2015 | $1,882,000 | -6.1% | 20,351 | 0.0% | 0.30% | -4.5% |
| Q2 2015 | $2,004,000 | -1.8% | 20,351 | 0.0% | 0.31% | +0.6% |
| Q1 2015 | $2,041,000 | +8.6% | 20,351 | 0.0% | 0.31% | +6.6% |
| Q4 2014 | $1,880,000 | – | 20,351 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |